Abstract: The present invention discloses a therapeutic system for the topic, transdermal and transcutaneous application of carbon monoxide (CO), comprising: (i) an adhesive layer, (ii) a gas-permeable and liquid- and solid-impermeable membrane, (iii) a reaction chamber comprising a CO releasing molecule A, and (iv) a gas-impermeable backing layer, wherein the transdermal therapeutic system is configured that the CO releasing molecule A can be brought into contact with a CO release triggering compound B in the reaction chamber (iii). The therapeutic system can be used for the treatment of wounds, inflammatory diseases of the skin, and inflammatory diseases of subcutaneous skin tissue, joints and tendons.

Abstract: An application of omega-3 and/or omega-6 fatty acid(s) for the therapeutic treatment of the human or animal body in the case of an impaired sphingolipid metabolism, in particular in the case of impaired sphingolipid synthesis and/or excessive sphingolipid degradation. The agent is applied in the case of missing, reduced and/or defective formation of a sphingomyelin synthase enzyme in the body, in particular the enzyme sphingomyelin synthase 1 or the enzyme sphingomyelin synthase 2. The application has proved to be useful in the case of a defect of the sphingomyelin synthase 1 gene or of the sphingomyelin synthase 2 gene. The omega-3 and/or omega-6 fatty acid(s) preferably comprise(s) polyunsaturated omega-3 and/or omega-6 fatty acid(s), preferably EPA, DHA, DPA, ETA, 21:5n3 and/or SDA. A method for determining a cause of a disease in an animal or a human being and a device for carrying out the method are also provided.

Abstract: A vehicle, such as a rail vehicle, has an electrodynamic braking apparatus with at least one brake resistor. The at least one brake resistor forms a portion of the vehicle body shell that is permanently closed and over which air flows on the exterior, in particular, during travel of the vehicle. In the alternative, the brake resistor is arranged in the immediate vicinity of the permanently closed portion. The brake resistor conducts away heat outwardly to the environment via the permanently closed portion. There is also described a brake resistor for a vehicle, in particular for a rail vehicle, which is configured accordingly.

Abstract: A vehicle, such as a rail vehicle, has an electrodynamic braking apparatus with at least one brake resistor. The at least one brake resistor forms a portion of the vehicle body shell that is permanently closed and over which air flows on the exterior, in particular, during travel of the vehicle. In the alternative, the brake resistor is arranged in the immediate vicinity of the permanently closed portion. The brake resistor conducts away heat outwardly to the environment via the permanently closed portion. There is also described a brake resistor for a vehicle, in particular for a rail vehicle, which is configured accordingly.

Abstract: An application of omega-3 and/or omega-6 fatty acid(s) for the therapeutic treatment of the human or animal body in the case of an impaired sphingolipid metabolism, in particular in the case of impaired sphingolipid synthesis and/or excessive sphingolipid degradation. The agent is applied in the case of missing, reduced and/or defective formation of a sphingomyelin synthase enzyme in the body, in particular the enzyme sphingomyelin synthase 1 or the enzyme sphingomyelin synthase 2. The application has proved to be useful in the case of a defect of the sphingomyelin synthase 1 gene or of the sphingomyelin synthase 2 gene. The omega-3 and/or omega-6 fatty acid(s) preferably comprise(s) polyunsaturated omega-3 and/or omega-6 fatty acid(s), preferably EPA, DHA, DPA, ETA, 21:5n3 and/or SDA. A method for determining a cause of a disease in an animal or a human being and a device for carrying out the method are also provided.